EmboLog® S – Dosage / Administration
instructions for use
brochure
Summary of safety and clinical performance (SSCP)

EmboLog® S is intended for embolization of blood vessels, especially for the local application in minimal invasive treatment, such as intra-arterial occlusion in liver tumour therapy. The embolization effect of EmboLog® S leads to a short-term vascular occlusion of blood vessels and reduced blood flow.

When cytostatic drugs are administered prior to the intended embolization, the effect of EmboLog® S leads to an increased duration of exposure of the cytostatic drug at the target area.

Depending on the size and vascularisation of the tumour, the arterial blood flow and the arteriovenous shunt volume, EmboLog® S can be given at a dosage of between 2.5 and 7.5 ml (150 – 450 mg). A maximum dose of 15 ml/900 mg is possible in special cases. Local chemotherapy can be carried out in several cycles lasting several days at intervals of 2 – 6 weeks. It is advisable to perform a check angiography at about 5 to 10 minute intervals to rule out any back-flow.

When EmboLog® S is used, a desirable, optimal slowing of blood flow in the tumour-bearing organ / organ segment can be recorded individually by angiographic monitoring. To do this, the tip of the catheter used should be positioned selectively in the vicinity of the tumour via the artery of the target organ.